Macrolide-resistant Mycoplasma pneumoniae resurgence in Chinese children in 2023: a longitudinal, cross-sectional, genomic epidemiology study
The Lancet Microbe · 2025
DOI: 10.1016/j.lanmic.2025.101200 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift The Lancet Microbe, 2025. Verfasst von Chao Yan und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China. Hauptthemen laut MEDLINE: Mycoplasma pneumoniae, Pneumonia, Mycoplasma, Macrolides, Drug Resistance, Bacterial. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China, National Key Research and Development Program of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: After a prolonged period of low detection rates, Mycoplasma pneumoniae resurged in China, during September to November, 2023, raising global concern. This study aims to gain a better understanding of the genetic mechanisms underlying the 2023 increase in cases and the evolutionary dynamics of the epidemic populations, which has been previously hampered due to limited genomic data of this pathogen. METHODS: We sequenced 685 M pneumoniae isolates, including 248 isolates from 11 Chinese provinces and municipalities in 2023 and 437 isolates from Beijing (2013-22). By analysing these isolates and 436 publicly global sequences, we reconstructed the pathogen's evolutionary history using time-calibrated phylogenies and effective population size inference. We investigated potential genomic variations contributing to the 2023 resurgence through genome-wide association study and conducted phylogeographic analysis of the 2023 isolates across China. FINDINGS: Two macrolide-resistant epidemic clusters (T1-2-EC1 and T2-2-EC2) were responsible for the 2023 resurgence in China. Both clusters, having acquired the 23S ribosomal RNA A2063G mutation conferring macrolide resistance, emerged in approximately 1997 and 2014, respectively, and subsequently outcompeted their predecessor populations. This coincided with China's large-scale adoption of azithromycin for paediatric community-acquired pneumonia around the early 2000s. Aside from macrolide resistance, T1-2-EC1 independently acquired 17 clade-specific mutations and T2-2-EC2 four clade-specific mutations, which could further explain their increased competitiveness. Whole-genome analysis revealed no resurgence-specific mutations in the 2023 isolates. Phylogeographic analysis showed rapid mixing of T1-2-EC1 isolates between different sampled regions within China. INTERPRETATION: Our study provides evidence that the 2023 resurgence in China is a continuation of the pre-COVID epidemic, rather than emergence of novel variants. The high prevalence of macrolide resistance and rapid intranational spread emphasise the urgent need for enhanced global surveillance of this pathogen. FUNDING: National Key Research and Development Program of China, National Natural Science Foundation of China for Key Programs of China Grants, and Beijing High-Level Public Health Technical Talent Project.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
- State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
- Laboratory of Virology, Capital Center for Children's Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
- Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou, China.
- Department of Pediatric Respiratory Medicine, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Intensive Care Unit, Maternal and Child Health Care Hospital of Binyang, Nanning, China.
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- National Key Research and Development Program of China
- Beijing Municipal Health Commission
Zitieren
APA
Yan, C., Tong, S., Wu, Y., Chen, Y., Jia, X., Guo, Y., Cui, M., Pei, G., Zhang, Z., Zhou, H., Mu, K., Ren, X., Du, B., Zhao, H., Feng, Y., Cui, J., Xia, Y., Wang, Z., Sun, Y., …, & Cui, Y. (2025). Macrolide-resistant Mycoplasma pneumoniae resurgence in Chinese children in 2023: a longitudinal, cross-sectional, genomic epidemiology study. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101200
Vancouver
Yan C, Tong S, Wu Y, Chen Y, Jia X, Guo Y, et al. Macrolide-resistant Mycoplasma pneumoniae resurgence in Chinese children in 2023: a longitudinal, cross-sectional, genomic epidemiology study. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2025.101200
BibTeX
@article{Yan2025,
author = {Yan, Chao and Tong, Shanwei and Wu, Yarong and Chen, Yujie and Jia, Xinyu and Guo, Yan and Cui, Mengnan and Pei, Guangqian and Zhang, Zuming and Zhou, Hao and Mu, Kai and Ren, Xue and Du, Bing and Zhao, Hanqing and Feng, Yanling and Cui, Jinghua and Xia, Yuyan and Wang, Zhen and Sun, Yu and Zhao, Linqing and Hao, Chuangli and Zhu, Zhijie and Luo, Shengqiang and Zhang, Han and Wang, Yongjun and Zhong, Lili and Chen, Dehui and Han, Zhiying and Yin, Yong and Hu, Longji and Ke, Yuehua and Xue, Guanhua and Cao, Ling and Didelot, Xavier and Yuan, Jing and Cui, Yujun},
title = {Macrolide-resistant Mycoplasma pneumoniae resurgence in Chinese children in 2023: a longitudinal, cross-sectional, genomic epidemiology study},
journal = {The Lancet Microbe},
year = {2025},
doi = {10.1016/j.lanmic.2025.101200}
}
EUVIMED